Skip to main content
spacbrain

PROKIDNEY CORP.

Closed (deSPAC)

Health Care · cellular therapy for chronic kidney disease · founded 2015

What it is
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research
What it’s doing now
Merging with Social Capital Suvretta Holdings Corp. III (DNAC) — closed (despac).
What you should know
The deal carries a $500M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT ™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT ™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com. 2

Source: S-4, accession 0001140361-25-011383

What the company says about itself

Web research — not audited

ProKidney is a late-clinical-stage biotechnology company pioneering a novel autologous cell therapy (rilparencel) designed to preserve kidney function in patients with advanced chronic kidney disease at high risk of kidney failure.

Markets:
Biotechnology | Cell Therapy | Nephrology / Chronic Kidney Disease
Products:
Rilparencel renal autologous cell therapy
What our web check found

[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction also includes a $575 million equity placement that will provide ProKidney with as much as $825 million in cash proceeds" [https://www.facebook.com/winstonsalemjournal/posts/prokidney-corp-reported-monday-a-second-quarter-loss-of-464-million-compared-wit/1650370977094269/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "ProKidney Announces the Closing of $140 Million Public Offering. ProKidney sold 46,886,452 Class A ordinary shares to the public ・ at a price" [https://investors.prokidney.com/news-releases/news-release-details/prokidney-announces-closing-140-million-public-offering-class/]

Source: https://prokidney.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

PROKIDNEY CORP. is merging with Social Capital Suvretta Holdings Corp. III (DNAC) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $575M · unsourced
Minimum cash to close$500M

Structure per SEC accession(s) 0001193125-22-172036. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is PROKIDNEY CORP. going public?

PROKIDNEY CORP. has an approved merger with the SPAC Social Capital Suvretta Holdings Corp. III (DNAC). Deal status: Closed (deSPAC).

Does PROKIDNEY CORP. have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals